Teneligliptin (hydrobromide)

Teneligliptin (MP-513) hydrobromide is an orally active and selective dipeptidyl peptidase 4 (DPP-4) inhibitor (IC50s: 0.37 and 0.29 nM for the human and rat DPP-4, respectively) . Teneligliptin hydrobromide improves blood glucose levels and can be used in researches related to type 2 diabetes mellitus[1][2][3][4][5][6][7][8].

Product Specifications

CAS Number

[906093-29-6]

Product Name Alternative

MP-513 (hydrobromide)

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

AMPK; Apoptosis; Dipeptidyl Peptidase; Interleukin Related; JNK; NF-κB; NOD-like Receptor (NLR) ; p38 MAPK; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Teneligliptin-hydrobromide.html

Purity

99.99

Solubility

DMSO : ≥ 100 mg/mL|H2O : ≥ 200 mg/mL

Smiles

O=C(N1CSCC1)[C@H]2NC[C@@H](N3CCN(C4=CC(C)=NN4C5=CC=CC=C5)CC3)C2.[2.5HBr]

Molecular Formula

C22H30N6OS.5/2HBr

Molecular Weight

628.86

Precautions

H302, H315, H319, H335

References & Citations

[1]Yoshida T, et al. Discovery and preclinical profile of teneligliptin (3-[ (2S,4S) -4-[4- (3-methyl-1-phenyl-1H-pyrazol-5-yl) piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine) : a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem. 2012 Oct 1;20 (19) :5705-19.|[2]Guo D, et al. Beneficial effects of combination therapy of canagliflozin and teneligliptin on diabetic polyneuropathy and β-cell volume density in spontaneously type 2 diabetic Goto-Kakizaki rats. Metabolism. 2020 Jun;107:154232.|[3]Zhang GL, et al. Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome. World J Diabetes. 2024 Apr 15;15 (4) :724-734.|[4]Fukuda-Tsuru S, et al. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice. Eur J Pharmacol. 2014 Jan 15;723:207-15.|[5]Zhang Z, et al. Teneligliptin protects against hypoxia/reoxygenation-induced endothelial cell injury. Biomed Pharmacother. 2019 Jan;109:468-474.|[6]Peng W, et al. Teneligliptin prevents doxorubicin-induced inflammation and apoptosis in H9c2 cells. Arch Biochem Biophys. 2020 Apr 15;683:108238.|[7]Liu X, et al. Teneligliptin inhibits lipopolysaccharide-induced cytotoxicity and inflammation in dental pulp cells. Int Immunopharmacol. 2019 Aug;73:57-63.|[8]Elumalai S, et al. High glucose-induced PRDX3 acetylation contributes to glucotoxicity in pancreatic β-cells: Prevention by Teneligliptin. Free Radic Biol Med. 2020 Nov 20;160:618-629.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

DPP-4; p38 MAPK

Citation 01

Cosmetics. 2024 Mar 1, 11 (2), 35.|Antioxidants (Basel) . 2021 Sep 9;10 (9) :1438.|Antioxidants (Basel) . 2023 Jul 24;12 (7) :1478.|Chem Res Toxicol. 2020 Aug 17;33 (8) :2164-2171.|Eur J Med Chem. 2021 Feb 15;212:113030.|Nephrol Dial Transplant. 2019 Oct 1;34 (10) :1669-1680.